Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with biopsy proven advanced melanoma are eligible if there is measurable disease.~* Patients must have a life expectancy of at least 12 weeks.~* Prior surgery, immunotherapy, minimal chemotherapy (1 drug for less than 4 months), or radiotherapy for primary tumor is acceptable but must be completed at least 4 weeks from study entry, and patient should have completely recovered from such procedures.~* Patients must have a Zubrod performance status of 0-2.~* Patients must sign an informed consent.~* Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of ≥ 1500 cells/mm3, hemoglobin \> 8 g/dl, platelet count ≥ 100 000/mm3.~* Patients should have a normal hepatic function with a total bilirubin \< 1.5 the upper limit of normal (ULN) and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) \< 2 times the upper limit of normal (ULN),and adequate renal function as defined by a serum creatinine ≤ 1.5 times the ULN.~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and at least for 3 months.~* Patients with brain metastases are eligible if they have been appropriately treated, are asymptomatic~Exclusion Criteria:~* Pregnant women or nursing mothers are not eligible.~* Patients must not receive any other concurrent chemotherapy or radiation during this trial.~* Patients with severe medical problems that would interfere with the therapy are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy Combination (Type: EXPERIMENTAL): Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).